Abstract: Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display) are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide.

Abstract: The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated pH gradient ion exchange chromatography. In some aspects, the methods use a combination of pH gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. In some aspects, the methods use a stable ionic strength to optimize the pH gradient separation window to separate the polypeptide from charge variants. Such methods are useful for analyzing polypeptide, e.g. antibodies, with a pI greater than 9 or a pI less than 7. In some aspects, the invention provides a multiproduct method for the analysis of polypeptides of varying pI's.

Abstract: Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder.

Abstract: This invention relates generally to devices and methods for performing optical and electrochemical assays and, more particularly, to test devices, e.g., cartridges, methods and systems, wherein the test devices have an entry port configured to receive a test sample into a holding chamber; a first conduit having at least one lateral flow test strip; and a displacement device, such as a pneumatic pump, configured to move a portion of said test sample from said holding chamber into said first conduit. The present invention is particularly useful for performing immunoassays and/or electrochemical assays at the point-of-care.

Abstract: The present disclosure provides methods for reducing the viscosity of a cell lysate or tissue lysate by: contacting the cell lysate or tissue lysate with a compressible and open-cell foam filter having a pore size from about 0.65 mm to about 1.22 mm, compressing the filter to recover the lysate absorbed in the filter, and collecting the filtered lysate; and also provides kits therefor.

Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also referred to as scleroderma; SSc) and the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices, and test kits which comprise these markers, and also to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc subgroups.

Abstract: The present invention provides a cellular system for the detection of the presence of one or more antibody species in sample, preferably a serum or plasma sample. The method is in particular useful for the analysis of patients who have been sensitized against blood group antigens expressed on erythrocytes, platelets or granulocytes. The system uses fluorescence labeled cells specific for each antigen and hence, for each antibody species. Provided are the methods, system and diagnostic kits for performing the methods of the invention. In addition, the present invention discloses a method for removing antibodies from a sample such as a serum sample. Such a method is useful for absorbing antibodies from poly-agglutinating sera.

Abstract: The present technology regards the utilization of CEACAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CEACAM1 levels for the detection and diagnosis of melanoma.

Abstract: Identification of autoantibodies associated with Crohn's disease useful in diagnosis and management using an innovative protein array technology, namely nucleic acid programmable protein arrays (NAPPA) and applications relating thereto. Overall, reactivity of IgG autoantibodies was stronger than that of IgA autoantibodies; however, IgA autoantibodies showed greater differential reactivity between cases and controls. Four IgA autoantibodies against SNRPB, PRPH, PTTG1 and SNAI1 were newly identified with sensitivities above 15% at 95% specificity, among which anti-SNRPB-IgA had the highest sensitivity of 24.0%. Autoantibodies associated with specific disease subtypes were also found.

Abstract: Split enzyme reporter systems are disclosed for detecting an analyte in a mixture. Fragments of the split enzyme may be covalently bound to targeting domains that bind to target regions of an analyte, thereby causing formation of an active complex. Some split enzyme reporter systems can be used to detect an analyte without the use of analyte immobilization, blocking, or wash steps. Some reporter systems also enable rapid detection of the analyte of interest.

Abstract: An object of the present invention is to provide a method for efficiently identifying a polyubiquitinated substrate which is generally not easily identified. The method for identifying a polyubiquitinated substrate includes (1) a step of expressing a trypsin-resistant polyubiquitin chain-binding protein and a ubiquitin ligase in a cell, (2) a step of isolating a complex that contains the trypsin-resistant polyubiquitin chain-binding protein from the cell having undergone the step (1), (3) a step of subjecting the complex isolated by the step (2) to trypsin digestion, and (4) a step of identifying a peptide that has a ubiquitination site from a digested material obtained by the step (3).

Abstract: A device for incubating an immunoblot strip (6) includes at least one incubation channel (1) into which an elongate immunoblot strip (6) having at least one biological material on its front is inserted with its back facing a channel base (2). An agitating means (7), with which the immunoblot strip (6) is agitatable around a transverse axis (8) of the strip (6) at least at times during incubation via an agitating device (7). For handling and/or grouping incubation channels (1) with immunoblot strips (6) inserted, a rack (3) for taking up at least two incubation channels (1) is provided. The rack (3) is in operative connection with said agitating means (7) via load transmission points.

Abstract: The invention provides a method detecting free light chains (FLCs) comprising: (i) providing a sample from a subject; (ii) mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii) passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv) detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.

Abstract: A biosensor system for the detection of target analytes that includes a living biological cell of a predetermined type; a signal-generating reporter associated with the living biological cell; a signal transduction pathway or other activator mechanism or means associated with the signal-generating reporter; a universal detector element associated with the activator mechanism; and an analyte binding element associated with the universal detector element, wherein the analyte binding element is specific to both the universal detector element and a target analyte.

Abstract: The present invention is based on the finding that red blood cell antigens can be exploited as a means to detect red blood cells/erythrocytes. Specifically, by identifying red blood cell antigens which are expressed by substantially all red blood cell types, it is possible to provide a method which achieves the reliable detection of red blood cells.

Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.

Abstract: The present invention relates to a method for detecting molecules.

Abstract: The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. Also disclosed are kits comprising reagents for performing the methods as claimed.

Abstract: Materials, systems and methods are provided for qualitative assessment of exposure of a person to ionizing radiation by measuring amounts of the biomarkers, wherein a change compared with corresponding un-irradiated control reference ranges of the biomarkers, provides the assessment, wherein the biomarkers include (i) alpha-1-Antichymotrypsin (ACT), (ii) Fms-related tyrosine kinase 3 ligand (Flt3L), and (iii) one or more additional proteins.

Abstract: Disclosed are methods for screening for candidate compounds for hydrating the skin. The compounds selected according to the methods disclosed therein stimulate the intra-cellular amount and/or activity of TonEBP in keratinocytes. Preferably, the selected compounds induce a stimulation of at least 20%, preferably at least 50%, preferably at least 100% of the activity and/or intra-cellular amount of TonEBP.